Nov 20 (Reuters) - biOasis Technologies Inc BTI.V :
* BIOASIS ANNOUNCES POSITIVE RESULTS FROM PERIPHERAL WHOLE-BODY PET/CT SCAN STUDY IN NON-HUMAN PRIMATES WITH LEAD INVESTIGATIONAL CANDIDATE XB3-001TM
* BIOASIS TECHNOLOGIES INC SAYS FILED PATENT APPLICATIONS BASED ON OBSERVATIONS AND DATA MAY HAVE BROADER APPLICABILITY
* BIOASIS SAYS XB(3)-001 DEMONSTRATED LYMPHATIC SYSTEM PENETRATION AND MORE SELECTIVE TISSUE DISTRIBUTION WITH XB(3)-001 THAN TRASTUZUMAB ALONE